Analysts expect Edwards Lifesciences Corp (NYSE:EW) to post $966.58 million in sales for the current quarter, according to Zacks Investment Research. Ten analysts have made estimates for Edwards Lifesciences’ earnings. The highest sales estimate is $979.54 million and the lowest is $954.50 million. Edwards Lifesciences posted sales of $841.80 million during the same quarter last year, which suggests a positive year over year growth rate of 14.8%. The company is scheduled to report its next earnings results on Wednesday, July 25th.

On average, analysts expect that Edwards Lifesciences will report full year sales of $3.84 billion for the current financial year, with estimates ranging from $3.79 billion to $3.87 billion. For the next fiscal year, analysts anticipate that the business will post sales of $4.20 billion per share, with estimates ranging from $4.02 billion to $4.34 billion. Zacks’ sales calculations are an average based on a survey of sell-side research firms that follow Edwards Lifesciences.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Tuesday, April 24th. The medical research company reported $1.22 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.11 by $0.11. The company had revenue of $938.00 million during the quarter, compared to analyst estimates of $936.69 million. Edwards Lifesciences had a net margin of 17.36% and a return on equity of 28.60%. The company’s revenue for the quarter was up 6.2% on a year-over-year basis. During the same quarter last year, the business posted $0.94 EPS.

A number of equities research analysts have issued reports on the stock. ValuEngine lowered shares of Edwards Lifesciences from a “buy” rating to a “hold” rating in a research note on Wednesday, June 6th. SunTrust Banks reissued a “buy” rating and set a $180.00 target price on shares of Edwards Lifesciences in a research note on Tuesday, April 10th. Royal Bank of Canada lifted their target price on shares of Edwards Lifesciences to $145.00 and gave the company an “outperform” rating in a research note on Wednesday, May 23rd. Zacks Investment Research lowered shares of Edwards Lifesciences from a “buy” rating to a “hold” rating in a research note on Wednesday, April 4th. Finally, Cowen reissued a “buy” rating and set a $165.00 target price on shares of Edwards Lifesciences in a research note on Tuesday, March 20th. Five analysts have rated the stock with a hold rating and sixteen have given a buy rating to the stock. The company has an average rating of “Buy” and an average target price of $149.06.

In related news, VP Catherine M. Szyman sold 9,815 shares of Edwards Lifesciences stock in a transaction on Thursday, May 24th. The shares were sold at an average price of $139.39, for a total value of $1,368,112.85. Following the transaction, the vice president now owns 20,012 shares in the company, valued at approximately $2,789,472.68. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Michael A. Mussallem sold 32,900 shares of Edwards Lifesciences stock in a transaction on Thursday, May 17th. The stock was sold at an average price of $135.88, for a total transaction of $4,470,452.00. Following the completion of the transaction, the chief executive officer now owns 112,731 shares in the company, valued at approximately $15,317,888.28. The disclosure for this sale can be found here. In the last ninety days, insiders sold 260,882 shares of company stock valued at $35,667,612. 1.84% of the stock is owned by company insiders.

Institutional investors and hedge funds have recently made changes to their positions in the stock. Optimum Investment Advisors bought a new position in shares of Edwards Lifesciences during the 1st quarter worth about $110,000. IHT Wealth Management LLC increased its holdings in shares of Edwards Lifesciences by 84.6% during the 1st quarter. IHT Wealth Management LLC now owns 932 shares of the medical research company’s stock worth $126,000 after purchasing an additional 427 shares during the period. Well Done LLC bought a new position in shares of Edwards Lifesciences during the 1st quarter worth about $152,000. Peregrine Asset Advisers Inc. bought a new position in shares of Edwards Lifesciences during the 1st quarter worth about $204,000. Finally, Cetera Advisor Networks LLC bought a new position in shares of Edwards Lifesciences during the 1st quarter worth about $206,000. Hedge funds and other institutional investors own 80.71% of the company’s stock.

Shares of NYSE:EW traded up $0.69 during trading on Monday, reaching $152.87. 1,075,527 shares of the company traded hands, compared to its average volume of 1,275,233. The firm has a market capitalization of $32.08 billion, a P/E ratio of 40.23, a price-to-earnings-growth ratio of 2.23 and a beta of 0.65. Edwards Lifesciences has a 1-year low of $100.20 and a 1-year high of $155.22. The company has a quick ratio of 1.63, a current ratio of 2.07 and a debt-to-equity ratio of 0.14.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies to treat structural heart disease and critically ill patients in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic heart valves and related delivery systems for the nonsurgical replacement of heart valves.

Get a free copy of the Zacks research report on Edwards Lifesciences (EW)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.